Business Context and Reporting Period
This summary covers the Form 10-Q for Point Capital, Inc. (not Silo Pharma, Inc., as indicated in the metadata) for the quarter and six months ended June 30, 2018. Point Capital is a closed-end, non-diversified Business Development Company (BDC) regulated under the Investment Company Act of 1940. The company failed its Regulated Investment Company (RIC) diversification test in March 2017 due to over-concentration in a single portfolio company and is now subject to corporate income tax. Management is currently not making new investments and is considering strategic options including liquidation, merger, or withdrawing its BDC election.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2018 | Six Months Ended June 30, 2017 |
|---|---|---|
| Total Assets | $1,349,800 | $1,641,385 |
| Cash and Cash Equivalents | $776,208 | $365,960 |
| Investments at Fair Value | $558,125 | $1,320,229 |
| Net Investment Income (Loss) | ($210,937) | ($209,400) |
| Net Realized Gain (Loss) | $521,473 | $1,034 |
| Net Unrealized Gain (Loss) | ($608,901) | $877,161 |
| Net Increase (Decrease) in Net Assets | ($298,365) | $668,795 |
| Net Assets | $904,677 | $1,515,301 |
| Net Asset Value (NAV) per Share | $0.02 | $0.03 |
| Operating Expenses | $210,963 | $223,374 |
Material Changes vs. Prior Period
- Portfolio Valuation Decline: Total investment fair value dropped from $1.32 million to $558,125, a decrease of approximately 58%. This was primarily driven by a significant unrealized loss of approximately $654,656 related to the company's largest holding, IPSIDY INC. (IDTY).
- Realized Gains: The company recognized a net realized gain of $521,473 for the six months ended June 30, 2018, compared to $1,034 in the prior year. This gain was largely due to the sale of IPSIDY shares ($615,742 gain) offset by losses from warrant expirations and the sale of Orbital Tracking Corp.
- Cash Position: Cash and cash equivalents increased significantly to $776,208 from $294,591 at year-end 2017, driven by proceeds from the sale of investments ($679,676).
- Concentration Risk: As of June 30, 2018, approximately 97% of the portfolio's fair value was concentrated in IPSIDY INC. (Biometric Technology), up from 70% in common stock and 37% in warrants at year-end 2017.
Outlook, Risks, and Management Commentary
- Strategic Uncertainty: Management is not making new investments. The company is evaluating options including liquidation, merging with another BDC or operating company, or withdrawing its BDC election.
- Tax Status: The company lost its RIC status in 2017 and is subject to corporate income tax rates. It does not intend to regain RIC status.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2018. Material weaknesses were identified, including a lack of segregation of duties, lack of experienced internal staff, and the recent resignation of the CFO (who remains a consultant).
- Liquidity: The company believes existing cash ($776,208) is sufficient to meet working capital requirements for at least 12 months. There are no current agreements to raise capital.
- Preferred Stock: $400,000 of Series A Convertible Preferred Stock is outstanding. While the company is not currently in breach of reporting obligations, failure to meet asset coverage requirements or other triggering events could force redemption.
Key Facts for Investor Verification
- Company Identity: Verify the filing is for Point Capital, Inc., not Silo Pharma, Inc.
- Single Asset Concentration: Confirm the valuation methodology and current status of IPSIDY INC., which represents ~97% of the investment portfolio.
- Internal Control Weaknesses: Review the specific material weaknesses regarding financial reporting and the impact of the CFO's resignation.
- Strategic Direction: Monitor for announcements regarding liquidation, merger, or withdrawal of BDC status, as the company is currently in a holding pattern.
- Preferred Stock Triggers: Assess the risk of redemption triggers for the $400,000 Series A Preferred Stock, particularly regarding asset coverage ratios.